Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323867 | 0.96 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20146346 | 0.96 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20146348 | 0.88 | HTR2C (0.43) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL22039244 | 0.84 | HTR2C (0.40) | HTR2CSMN1; SMN2NPC1RAB9APDK1 | |
| SCHEMBL20146366 | 0.83 | HTR2C (0.49) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20146347 | 0.83 | HTR2C (0.39) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20146450 | 0.81 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20323941 | 0.79 | HTR2C (0.47) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL21538652 | 0.77 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL20146358 | 0.75 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAPAN TOBACCO INC. (JP) | 2022-05-24 | — | — | US | disclosed |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAPAN TOBACCO INC. (JP) | 2020-11-03 | — | — | US | disclosed |
| EP-3321271-A1 | METHOD FOR PRODUCING 7H-PYRROLO[2, 3-D]PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Japan Tobacco, Inc. (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339181-B2 | Crystalline forms of a Janus kinase inhibitor | JAK1, JAK3, JAK2 | HTR2C 2648/4885SMN1; SMN2 4747/4885NPC1 3576/4885 |
| US-10822354-B2 | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof | JAK1, JAK3, JAK2 | HTR2C 1522/4885SMN1; SMN2 4192/4885NPC1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.